Clinical Trial Update: Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports results from Phase 2 and Phase 3 studies evaluating azacitidine with or without nivolumab or midostaurin, or decitabine with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CYTARABINE (CYTARABINE)
• Decitabine (Decitabine)
• Midostaurin (midostaurin)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-07-23